Multimodal Prehabilitation for Resectable Gastric Cancer

Sponsor
Chinese PLA General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05714878
Collaborator
(none)
70
2
11

Study Details

Study Description

Brief Summary

Surgical resection is the mainstay for gastric cancer. Surgical stress response, like insulin resistance and catabolism, is inevitable and is a risk factor for postoperative outcome. To cope with this stress, the enhanced recovery protocol has been proposed and successfully implemented in clinical practice. Recently, prehabilitation have attracted increasingly attention, which is the preoperative part of enhanced recovery pathway. Prehabtilitation are bundles of evidenced elements in order to improve patient's functional capacity. Patients with gastric cancer are usually suffered from nutritional risk, anxiety and frailty. In this trial, we investigate whether multimodal prehabilitation (exercise, nutrition and psychological support) could improve patient's functional status to better tolerate surgical trauma.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: aerobic exercise; resistance exercise; nutritional support; psychological support
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Multimodal Prehabilitation for Patients With Resectable Gastric Cancer: A Randomized Controlled Trial
Anticipated Study Start Date :
Jan 31, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prehabilitation arm

Patient receives prehabilitation intervention including exercise, nutrition and psychological support.

Behavioral: aerobic exercise; resistance exercise; nutritional support; psychological support
Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.

No Intervention: Control arm

Patient receives regular care recommended by the WHO without supervision and support.

Outcome Measures

Primary Outcome Measures

  1. Duke Activity Status Index before surgery [Duke Activity Status Index score on the day before surgery]

    Duke Activity Status Index score is a 12-item self-reported questionnaire that assesses daily activities such as personal care, ambulation, household tasks, and recreation with respective metabolic costs. Duke Activity Status Index score ranges from 0 to 58.2. The higher score indicates the better functional status. Duke Activity Status Index has been recommended by European Society of Cardiology guidelines for functional assessment of patients undergoing non-cardiac surgery.

Secondary Outcome Measures

  1. Morbidity [In postoperative 30 day after gastrectomy]

    Postoperative complication

  2. Postoperative hospital stay [During the postoperative 30 day period]

    Period from day of surgery to day of discharge from hospital

  3. 30-day readmission rate [During the postoperative 30 day period]

    Proportion of patients admitted to the hospital after discharge because of complications

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pathologically confirmed gastric cancer, clinical I-III TNM stage (AJCC 8th edition);

  • Will receive curative-intent surgery;

  • Life expectance > 6 months;

Exclusion Criteria:
  • Gastric stump cancer or combined with other malignances;

  • NYHA III, NYHA IV;

  • Inability to swallow, with gastrostomy, or inability to move because of orthopedic disease or neuromuscular disease;

  • Psychiatric disorders, COPD, end-stage hepatic or renal disease, uncontrolled cardiac arhythmia or uncontrolled hypertention;

  • Receiving immunosuppressive therapy;

  • Emergency surgery because of tumor bleeding or tumor perforation;

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Chinese PLA General Hospital

Investigators

  • Principal Investigator: Kecheng Zhang, Chinese PLA General Hospital First Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Kecheng Zhang, Principal Investigator, Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT05714878
Other Study ID Numbers:
  • PLAGH202212
First Posted:
Feb 6, 2023
Last Update Posted:
Feb 6, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kecheng Zhang, Principal Investigator, Chinese PLA General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 6, 2023